ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Saturday, November 7, 2020

9:00AM-11:00AM: Abstract Number: 0658

Identification of Two Novel Dysfunctional Variants in a Physiologically Important Urate Transporter ABCG2 in Paediatric-onset Familial Hyperuricemia and Gout Patients in Three Generations

Metabolic & Crystal Arthropathies Poster

9:00AM-11:00AM: Abstract Number: 0866

Identifying an SLE Patient Cluster with Greater Treatment Effect: Immune Cell Deconvolution of Gene Expression in Two Atacicept Phase II Studies

SLE – Treatment Poster I

9:00AM-11:00AM: Abstract Number: 0823

Identifying Physician-Perceived Barriers to a Pragmatic Treatment Trial in Rheumatoid Arthritis

RA – Treatments Poster II: Comparative Effectiveness, Biosimilars, Adherence & the Real World

9:00AM-11:00AM: Abstract Number: 0639

Immunological Abnormalities in a SARS-CoV-2-Cytokine Release Syndrome Rheumatology Cohort

Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 0598

Impact of a Dedicated Lupus Nephritis Clinic to Improve Time to Biopsy and Care Quality

Health Services Research Poster

9:00AM-11:00AM: Abstract Number: 0614

Impact of COVID-19 Pandemic on the Rheumatology Practice in Mexico: Mexican College of Rheumatology Survey

Health Services Research Poster

9:00AM-11:00AM: Abstract Number: 0609

Impact of Depressive Symptoms, Anti-depression Treatment on Direct Medical Costs Among Medicare Beneficiaries with Knee Osteoarthritis (KOA)

Health Services Research Poster

9:00AM-11:00AM: Abstract Number: 0902

Impact of Dose Escalation of Secukinumab in Patients with Psoriatic Arthritis in Real-World Setting

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 0911

Impact of Filgotinib on Structural Lesions in the Sacroiliac Joints at 12 Weeks in Patients with Active Ankylosing Spondylitis: Correlation with Clinical Endpoints

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 0885

Impact of HLA-B27 Status on Clinical Outcomes in Patients with Ankylosing Spondylitis Treated with Secukinumab

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 0847

Impact of Hydroxychloroquine Treatment on Immunologic Markers in SLE Depends on Ethnicity

SLE – Treatment Poster I

9:00AM-11:00AM: Abstract Number: 0868

Impact of Proteinuria on the Clearance of Monoclonal Antibodies: Potential Clinical Implications

SLE – Treatment Poster I

9:00AM-11:00AM: Abstract Number: 0873

Impact of Skin Involvement on Disease Burden Among Patients with Psoriatic Arthritis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 0896

Impact of Upadacitinib on Reducing Pain in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Trials in Patients with Inadequate Response to Non-biologic or Biologic DMARDs

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 0877

Improvements in Global Functioning and Health-related Quality of Life and Their Association with Disease Activity and Functional Improvement in Patients with Active Ankylosing Spondylitis Treated with Upadacitinib

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].